Pediatric Vaccines Market Size to hit Around USD 70.55 Billion by 2034

Pediatric Vaccines Market Size to hit Around USD 70.55 Billion by 2034

The pediatric vaccines market size was exhibited at USD 46.75 billion in 2024 and is projected to hit around USD 70.55 billion by 2034, growing at a CAGR of 4.2% during the forecast period 2025 to 2034.

Pediatric Vaccines Market Key Takeaways:

  • Monovalent dominated the market and accounted for a share of 56.0% in 2024.
  • The infectious disease segment dominated the market in 2024.
  • The measles, mumps, and rubella (MMR) segment is projected to grow at the fastest CAGR of 6.1% over the forecast period.
  • The conjugate vaccines segment dominated the market in 2024.
  • The live attenuated vaccines is projected to grow at the substantial rate over the forecast period.
  • North America dominated the pediatric vaccines market and accounted for a revenue share of 43.0% in 2024
  • The U.S. pediatric vaccines market dominated the North America market with a share of 78.1% in 2024.

?????????????? ?????? ???????? ???????????? ????????????: https://www.novaoneadvisor.com/report/sample/9048

U.S. Pediatric Vaccines Market Size and Growth 2025 to 2034

The U.S. pediatric vaccines market size is evaluated at USD 15.08 billion in 2024 and is projected to be worth around USD 22.75 billion by 2034, growing at a CAGR of 3.8% from 2025 to 2034.

North America dominated the pediatric vaccines market and accounted for a revenue share of 43.0% in 2024 due to immunisation coverage that is backed up by enough government support and funding of immunisation to ensure easy access to vaccines and strict compliance with immunisation schedules. Furthermore, the existing presence of big pharmaceuticals, the constant progress in the vaccine technology, and the good healthcare system that supports the market and promotion of new and advanced vaccines are anticipated to drive market growth in this region.

U.S. Pediatric Vaccines Market Trends

The U.S. pediatric vaccines market dominated the North America market with a share of 78.1% in 2024 due to developed healthcare infrastructure and government-supported immunization programs in the U.S. for pediatrics. This strong system guarantees a high level of vaccination and establishes stable demand for children’s vaccines and brings the U. S. market to the leading position.

Europe Pediatric Vaccines Market Trends

Europe pediatric vaccines market was identified as a lucrative region in 2024. First of all, there is concentration on the progresses of research and development of vaccines in Europe and the new creation of more effective vaccines. Furthermore, proper government support and grants for children's immunization services guarantee high rates of immunization and subsequently constant demand for children's vaccines across Europe.

UK pediatric vaccines market is expected to grow rapidly in the coming years due there is a rising importance of enhancing the immunisation routine for children in the UK, especially as many parents remain unconvinced of the need for vaccinations for their children with pertinent deadly diseases being eradicated. Additionally, an enhancement of public awareness of the need to get vaccinated and support from the government towards such programs are expected to propel the need for pediatric vaccines across UK.

Asia Pacific Pediatric Vaccines Market Trends

Asia Pacific pediatric vaccines market is anticipated to witness significant growth. As there is a significant rise in the population of children in the region which suggests a high demand for pediatric vaccines. Additionally, there is an increasing concern with the quality to health care facilities and for childhood immunization programs in many of the countries in Asia Pacific.

China pediatric vaccines market held a substantial market share in 2024 owing to China’s high birth rate and population growth, which means there is a constant stream of children that require immunization. Secondly, the government support for child immunization programs and efforts to enhance the population's awareness of immunization benefits also support more demand for pediatric vaccines in China.

Pediatric Vaccines Market By Type Insights

Monovalent vaccines led the market, capturing a 56.0% share in 2024. This dominance is driven by their focus on targeting a single pathogen, making them more appealing due to perceived therapeutic precision and fewer side effects compared to combination vaccines. This has resulted in higher acceptance among healthcare providers and parents. Furthermore, significant investments by major pharmaceutical companies in the production and distribution of monovalent vaccines have enhanced their global availability and accessibility.

Multivalent vaccines are anticipated to grow at the fastest compound annual growth rate (CAGR) of 4.3% during the forecast period. This growth is fueled by the demand for comprehensive immunization solutions that address multiple diseases through a single dose, aligning with the preferences of both healthcare providers and users. Advances in vaccine technology and ongoing research to develop new multivalent vaccines are also expanding their reach and efficacy. Government-backed immunization programs, particularly in regions with high disease prevalence, are increasingly prioritizing multivalent vaccines.

Pediatric Vaccines Market By Application Insights

The infectious disease segment held the largest market share in 2024. This is due to the high prevalence of infectious diseases such as measles, mumps, and rubella, which necessitate widespread vaccination efforts. Additionally, continuous advancements in vaccine development, coupled with strong governmental and international support for immunization initiatives, have driven the growth of this segment, ensuring the global supply of effective vaccines.

The measles, mumps, and rubella (MMR) segment is expected to grow at the fastest CAGR of 6.1% during the forecast period. This growth is attributed to ongoing cases of these diseases, particularly in regions with low vaccination coverage. Public health campaigns emphasizing the importance of MMR vaccination, along with increased international travel, are driving demand for this combination vaccine to protect children from these preventable illnesses.

Pediatric Vaccines Market By Technology Insights

Conjugate vaccines dominated the market in 2024. Their higher immunogenicity compared to traditional vaccines makes them more effective in stimulating robust immune responses, especially in children with weaker immune systems. This advantage, combined with their ability to target specific antigens, has established conjugate vaccines as a preferred option for many childhood immunization programs.

Live attenuated vaccines are projected to experience significant growth over the forecast period. These vaccines provide long-lasting immunity against diseases such as measles, mumps, and rubella, reducing the need for booster shots. Their high efficacy and cost-effectiveness make them ideal for use in large-scale immunization programs, particularly in developing nations.

Some of the prominent players in the pediatric vaccines market include:

Pediatric Vaccines Market Recent Developments

  • In March, 2024 European commission approved Pfizer's PREVENAR 20, a vaccine offering the broadest serotype coverage to protect children against pneumococcal disease. This approval is based on extensive Phase 3 trial data demonstrating its safety and effectiveness. It follows similar approvals in the U.S., Canada, Australia, and other countries.
  • In November, 2024 Indian Immunologicals Limited (IIL) has launched a new measles and rubella vaccine for children, named Mabella. Developed in partnership with the Polyvac Institute of Vietnam, the live-attenuated vaccine has undergone rigorous clinical trials, demonstrating both safety and efficacy. This launch coincides with the 25th anniversary of IIL’s Human Biologicals Institute, highlighting the company’s ongoing contributions to vaccine development and disease control in India.
  • In May, 2024 Phase IIIb HARMONIE trial data was presented at the European Society for Paediatric Infectious Diseases meeting which demonstrated that Beyfortus (nirsevimab) significantly reduced hospitalizations due to RSV lower respiratory tract infections in infants under 12 months by 83.2%. Additionally, it showed a 75.7% reduction in very severe RSV LRTI hospitalizations, with Beyfortus maintaining a favorable safety profile. These results reinforce Beyfortus' potential to significantly relieve the burden of RSV on healthcare systems and families.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the pediatric vaccines market

By Type

  • Monovalent
  • Multivalent

By Technology

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • Others

By Application

  • Infectious Disease
  • Cancer
  • Allergy
  • Pneumococcal Diseases
  • Influenza
  • Measles, Mumps, and Rubella (MMR)
  • Other Application

By?Regional

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/9048

Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to [email protected]| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with Us

Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

IND Address: 707, Nandan Probiz, Baner,?Pune (MH) – 411045, India

USA:?+1 804 441 9344

APAC:?+61 485 981 310 or +91 87933 22019

Europe:?+44 7383 092 044

Email: [email protected]

Web: https://www.novaoneadvisor.com/

You can place an order or ask any questions, please feel free to contact at?[email protected] ?| +1 804 441 9344

要查看或添加评论,请登录

Ramchandra Dige的更多文章

社区洞察

其他会员也浏览了